Last reviewed · How we verify
Recombinant human brain natriuretic peptide — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Recombinant human brain natriuretic peptide (Recombinant human brain natriuretic peptide) — Shanghai Zhongshan Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant human brain natriuretic peptide TARGET | Recombinant human brain natriuretic peptide | Shanghai Zhongshan Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant human brain natriuretic peptide CI watch — RSS
- Recombinant human brain natriuretic peptide CI watch — Atom
- Recombinant human brain natriuretic peptide CI watch — JSON
- Recombinant human brain natriuretic peptide alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant human brain natriuretic peptide — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-brain-natriuretic-peptide. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab